Memo inOncology SPECIAL ISSUE congress report WCLC – ESMO 2021 is now available!

Although the COVID-19 pandemic has still prevented on-site attendance at this year’s WCLC (September 8th – September 14th) and ESMO meeting (September 16th – September 21st), the global oncology community presented a large range of relevant and potentially practice-changing findings. This report summarizes important findings relating to the management of patients with lung cancer, starting with the expansion of treatments and insights in the early-stage disease setting. A multitude of studies investigating drugs targeting EGFR and HER2 are presented as well as checkpoint inhibition that is being implemented in other entities apart from NSCLC such as small-cell lung cancer and mesothelioma. Last but not least, this special issue includes a section about anti-cancer vaccination after failure of immune checkpoint inhibition and a first-in-class selective immunomodulating microtubule-binding agent that has the potential of a preferred second/third-line treatment option in the setting of NSCLC with EGFR wildtype.